Thiram: A dithiocarbamate chemical, used commercially in the rubber processing industry and as a fungicide. In vivo studies indicate that it inactivates the enzyme GLUTATHIONE REDUCTASE. It has mutagenic activity and may induce chromosomal aberrations. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
thiram : An organic disulfide that results from the formal oxidative dimerisation of N,N-dimethyldithiocarbamic acid. It is widely used as a fungicidal seed treatment. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5455 |
| CHEMBL ID | 120563 |
| CHEBI ID | 9495 |
| SCHEMBL ID | 21144 |
| MeSH ID | M0021389 |
| Synonym |
|---|
| nsc-59637 |
| BIDD:ER0359 |
| nsc-622696 |
| thioperoxydicarbonic diamide, tetramethyl- |
| vulkacit th |
| arasan |
| fernasan |
| thiurad |
| atiram |
| pomarsol forte |
| thiulix |
| tetramethylthiocarbamoyldisulphide |
| tetramethyl-thiram disulfid |
| spotrete |
| arasan 42-s |
| fernacol |
| thiram 80 |
| bis(dimethylthiocarbamoyl) disulfide |
| arasan-sf |
| vulkacit thiuram |
| thirame |
| tuex |
| thiuram m |
| disulfure de tetramethylthiourame |
| disolfuro di tetrametiltiourame |
| thiuram m rubber accelerator |
| tetramethylthiuram |
| fernide |
| tetrathiuram disulfide |
| tetramethylthiuram bisulfide |
| cyuram ds |
| tirampa |
| arasan 70-s red |
| thiuramyl |
| bis[(dimethylamino)carbonothioyl] disulfide |
| hexathir |
| accelerator thiuram |
| kregasan |
| thirasan |
| disulfide, bis(dimethylthiocarbamoyl) |
| n,n'-(dithiodicarbonothioyl)bis(n-methylmethanamine) |
| nobecutan |
| tetramethylthiurum disulfide |
| aceto tetd |
| mls002702972 , |
| mercuram |
| thiram b |
| thillate |
| trametan |
| thiuram |
| tetramethylthiuram disulfide |
| tetrasipton |
| formalsol |
| thiotox |
| normersan |
| thiotex |
| thiulin |
| sq 1489 |
| formamide,1'-dithiobis(n,n-dimethylthio- |
| arasan 70 |
| bis(dimethyl-thiocarbamoyl)-disulfid |
| tntd |
| puralin |
| vulkacit mtic |
| thioperoxydicarbonic diamide ([(h2n)c(s)]2s2), tetramethyl- |
| fernasan a |
| thioscabin |
| nsc-1771 |
| tetramethylenethiuram disulfide |
| methyl thiram |
| n,n',n'-tetramethylthiuram disulfide |
| n,n-tetramethylthiuram disulfide |
| hermal |
| nsc1771 , |
| vulcafor tmtd |
| thylate |
| accelerator t |
| pomasol |
| hermat tmt |
| thiram 75 |
| thiuram-m |
| thiramad |
| tetramethylthiuram disulphide |
| methylthiuram disulfide |
| tmtds |
| methyl tuads |
| arasan-m |
| bis(dimethylthiocarbamyl) disulfide |
| tiuramyl |
| arasan-sf-x |
| sadoplon 75 |
| aapirol |
| .alpha.,.alpha.'-dithiobis(dimethylthio)formamide |
| royal tmtd |
| arasan 42s |
| pomarsol |
| ekagom tb |
| tetramethylthioramdisulfide |
| tersantetramethyldiurane sulfide |
| tmtd |
| tetramethylthiurane disulfide |
| aatiram |
| arasan 75 |
| vuagt-i-4 |
| tuads |
| sadoplon |
| falitiram |
| fermide |
| tyradin |
| zaprawa nasienna t |
| wln: 1n1 & yus & ssyus & n1 & 1 |
| vulcafor tmt |
| tersan |
| tersan 75 |
| nomersan |
| tutan |
| tetramethylthioperoxydicarbonic acid [(h2n)c(s)]2s2 |
| heryl |
| tridipam |
| thiuram d |
| vancida tm-95 |
| tripomol |
| accel tmt |
| thiosan |
| rezifilm |
| teramethylthiuram disulfide |
| thiuram disulfide, tetramethyl- |
| panoram 75 |
| nsc-49512 |
| KBIO1_000741 |
| DIVK1C_000741 |
| NCIMECH_000272 |
| NCI60_001477 |
| NCI60_006736 |
| smr000059023 |
| MLS000069752 , |
| [dithiobis(carbonothioylnitrilo)]tetramethane |
| vanguard gf |
| SPECTRUM_001687 |
| SPECTRUM5_001653 |
| IDI1_000741 |
| nsc622696 |
| nsc59637 |
| nsc49512 |
| dimethylcarbamothioylsulfanyl n,n-dimethylcarbamodithioate |
| D06114 |
| thiram (usan/inn) |
| rezifilm (tn) |
| NCGC00091563-01 |
| tetramethylthiouram disulfide |
| tetramethylthiurum disulphide |
| spotrete-f |
| bis(dimethyl thiocarbamoyl)disulfide |
| aules |
| thirame [inn-french] |
| metiurac |
| n,n-tetramethylthiuram disulphide |
| thioperoxydicarbonic diamide (((h2n)c(s))2s2), tetramethyl- |
| radothiram |
| thirampa |
| methyl thiuramdisulfide |
| tetramethylenethiuram disulphide |
| tetrapom |
| micropearls |
| ent 987 |
| tetramethyl-thiram disulfid [german] |
| pol-thiuram |
| ai3-00987 |
| n,n,n',n'-tetramethylthiuram disulfide |
| orac tmtd |
| nsc 622696 |
| disolfuro di tetrametiltiourame [italian] |
| cunitex |
| alpha,alpha'-dithiobis(dimethylthio)formamide |
| rcra waste no. u244 |
| hsdb 863 |
| bis(dimethylthiocarbamoyl) disulphide |
| thioperoxydicarbonic diamide ((h2n)c(s))2s2, tetramethyl- |
| thimer |
| tetrathiuram disulphide |
| thioknock |
| fmc 2070 |
| fermide 850 |
| anles |
| tetramethyl thiuramdisulfide |
| epa pesticide chemical code 079801 |
| nsc 49512 |
| formamide, 1,1'-dithiobis(n,n-dimethylthio- |
| delsan |
| tetramethyl thiurane disulphide |
| tetramethylthioramdisulfide [dutch] |
| bis(dimethyl-thiocarbamoyl)-disulfid [german] |
| einecs 205-286-2 |
| flo pro t seed protectant |
| thiotox (fungicide) |
| nsc 1771 |
| thimar |
| rcra waste number u244 |
| tetramethylthiuran disulphide |
| bis((dimethylamino)carbonothioyl) disulfide |
| tetramethyl thiurane disulfide |
| thianosan |
| disulfuro di tetrametiltiourame [italian] |
| brn 1725821 |
| nsc 59637 |
| nocceler tt |
| chipco thiram 75 |
| hy-vic |
| bis((dimethylamino)carbonothioyl) disulphide |
| tetramethylthiuram bisulphide |
| caswell no. 856 |
| ccris 1282 |
| thiramum [inn-latin] |
| disulfure de tetramethylthiourame [french] |
| tetramethyldiurane sulphite |
| sranan-sf-x |
| thiram |
| tetramethylthioperoxydicarbonic diamide |
| 137-26-8 |
| tetramethylthiuram disulfide, 97% |
| NCGC00091563-03 |
| NCGC00091563-02 |
| NCGC00091563-04 |
| KBIO3_002684 |
| KBIOSS_002167 |
| KBIO2_002167 |
| KBIOGR_001499 |
| KBIO2_004735 |
| KBIO2_007303 |
| SPBIO_001428 |
| SPECTRUM3_001592 |
| SPECTRUM4_000860 |
| NINDS_000741 |
| NCIOPEN2_007854 |
| SPECTRUM2_001554 |
| SPECTRUM1503322 |
| BSPBIO_003184 |
| QTL1_000082 |
| NCGC00091563-06 |
| NCGC00091563-05 |
| HMS2093E03 |
| kuazqdvkqlnfpe-uhfffaoysa- |
| inchi=1/c6h12n2s4/c1-7(2)5(9)11-12-6(10)8(3)4/h1-4h3 |
| 1-(dimethylthiocarbamoyldisulfanyl)-n,n-dimethyl-methanethioamide |
| chebi:9495 , |
| sq-1489 |
| CHEMBL120563 |
| HMS502F03 |
| HMS1922A12 |
| AKOS000120200 |
| NCGC00091563-07 |
| NCGC00091563-08 |
| NCGC00091563-10 |
| NCGC00091563-09 |
| (dimethylamino){[(dimethylamino)thioxomethyl]disulfanyl}methane-1-thione |
| thioperoxydicarbonic diamide (((h2n)c(s))2s2), n,n,n',n'-tetramethyl- |
| granuflo |
| disulfuro di tetrametiltiourame |
| attack [antifungal] |
| 4-04-00-00242 (beilstein handbook reference) |
| 0d771is0fh , |
| unii-0d771is0fh |
| thiram [usan:inn:bsi:iso] |
| ec 205-286-2 |
| NCGC00255002-01 |
| cas-137-26-8 |
| tox21_301102 |
| dtxsid5021332 , |
| dtxcid401332 |
| NCGC00259118-01 |
| tox21_201569 |
| B0486 |
| BMSE000928 |
| pharmakon1600-01503322 |
| nsc-758454 |
| nsc758454 |
| tox21_111150 |
| thiramum |
| HMS2234B08 |
| CCG-35460 , |
| n(1),n(1),n(3),n(3)-tetramethyl-2-dithioperoxy-1,3-dithiodicarbonic diamide |
| [disulfanediylbis(carbonothioylnitrilo)]tetramethane |
| tiramo |
| [me2nc(s)s]2 |
| FT-0631799 |
| thiram [iarc] |
| thiram [usan] |
| thiram [mi] |
| thiram [iso] |
| thiram [hsdb] |
| tetramethylthioperoxydicarbonic diamide ((((ch(sub 3))(sub 2)n)c(s))(sub 2)s(sub 2)) |
| thiram [inn] |
| thiram [mart.] |
| thiram [inci] |
| thiram [who-dd] |
| S2431 |
| STL264104 |
| HMS3374C05 |
| SCHEMBL21144 |
| NCGC00091563-12 |
| tox21_111150_1 |
| n,n-dimethylcarbamodithioic acid (dimethylthiocarbamoylthio) ester |
| n,n-dimethylcarbamodithioic acid [[dimethylamino(sulfanylidene)methyl]thio] ester |
| cid_5455 |
| bdbm43362 |
| bis (dimethyl thiocarbamoyl) disulfide |
| tetramethyl thiuram disulfide |
| thiram, certified reference material, tracecert(r) |
| vancide tm |
| thiuramin |
| spotrete wp 75 |
| ent-987 |
| agrichem flowable thiram |
| vulkacit dtmt |
| perkacit tmtd |
| arasan 50 red |
| akrochem tmtd |
| betoxin |
| naftocit thiuram 16 |
| accelerant t |
| vancide tm-95 |
| basultra |
| vulkazam s |
| thioperoxydicarbonic diamide ([(h2n)c(s)]2s2), n,n,n',n'-tetramethyl- |
| robac tmt |
| bis(dimethylaminothiocarbonyl)disulfide |
| tiradin |
| arasan m |
| KS-5354 |
| AB00052345_10 |
| bis(dimethylaminothiocarbonyl) disulfide |
| J-524968 |
| n,n-dimethyl[(dimethylcarbamothioyl)disulfanyl]carbothioamide |
| F0001-0468 |
| mfcd00008325 |
| sr-01000736911 |
| SR-01000736911-2 |
| thiram, pestanal(r), analytical standard |
| J-006992 |
| SBI-0051813.P002 |
| CS-0012858 |
| ziram metabolite |
| Q416572 |
| DB13245 |
| BRD-K29254801-001-06-3 |
| n,n-dimethyl[(dimethylcarbamothioyl)-disulfanyl]carbothioamide |
| D97716 |
| EN300-16677 |
| Z56754480 |
Thiram is an undetectable, relatively safe and accessible compound that can induce CTA in canids. Thiram (TMTD) is a widely used dithiocarbamate pesticide and fungicide and is one of potent contact allergens.
Thiram has been considered a common cause of tibial dyschondrolplasia (TD) in various avian species. It becomes the part of feed due to environmental contamination and its overuse in agriculture as pesticides or fungicide. Thiram could be used as a CFA agent in wildlife management and conservation to reduce predation by wild canids.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Thiram has been considered a common cause of tibial dyschondrolplasia (TD) in various avian species, because it becomes the part of feed due to environmental contamination and its overuse in agriculture as pesticides or fungicide." | ( Effect of tetramethyl thiuram disulfide (thiram) in relation to tibial dyschondroplasia in chickens. Iqbal, M; Jiang, X; Li, A; Li, J; Mehmood, K; Rehman, MU; Shen, Y; Waqas, M; Yao, W; Zhang, H, 2018) | 1.47 |
| "Thiram has the potential to be used as a CFA agent in wildlife management and conservation to reduce predation by wild canids. " | ( Conditioned food aversion in domestic dogs induced by thiram. Ferreras, P; García-Fernández, AJ; Gómez-Ramírez, P; Mateo, R; Tobajas, J, 2020) | 2.25 |
| "Thiram has been reported to inhibit dopamine-beta-hydroxylase (D beta H), thereby affecting norepinephrine (NE) synthesis. " | ( The dithiocarbamate fungicide thiram disrupts the hormonal control of ovulation in the female rat. Cooper, RL; Goldman, JM; Stoker, TE, ) | 1.86 |
| "Thiram has caused marginal increase in the relative weight of testes and epididymis and decrease in the weight of seminal vesicle and prostate." | ( Testicular toxicity in rat to repeated oral administration of tetramethylthiuram disulfide (Thiram). Mishra, VK; Raizada, RB; Srivastava, MK, 1998) | 1.24 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The thirame rats had a lower food intake than the others and the smallest body weight, but their relative liver and kidneys weights were the highest." | ( [Short term effects of diets with high levels of dithiocarbamates on carbohydrate and lipid metabolism of rat liver]. Dupuy, F; Faudemay, F; Griffaton, G; Lowy, R; Rozen, R, 1976) | 0.74 |
Thiram treatment significantly reduced the performance of chickens, liver index, and tibial length compared with control group. The thiramtreatment resulted in oxidative stress through an increase in hydrogen peroxide (H.P) Thiram also increased activities of SOD1, Se-dependent GSH-Px, and GR at the highest dose.
The toxic effect of thiram, a widely used dithiocarbamate fungicide, was investigated in cultured human skin fibroblasts. Ferbam and Thiram were more toxic on the basis of weight than zineb; maneb was relatively nontoxic.
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the case of the combination with Propoxur the effects appeared to be less than additive in males and strictly additive in females." | ( An evaluation of the toxicity of thiuram in combination with other pesticides. Brzeziński, J; Gradowska, I; Osicka, A; Wysocka-Paruszewska, B, 1980) | 0.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| " The bioavailability of thiram adsorbed by PVC and PET increased significantly." | ( Interaction and mechanistic studies of thiram and common microplastics in food and associated changes in hazard. Chen, Y; Chen, Z; Guo, Y; Liu, Q; Qian, H; Wu, D; Xie, Y; Yao, W; Yu, H; Yuan, S, 2024) | 2.02 |
intramuscular injection of the chVEGF proteins significantly reduced the severity of TD but had no effect on TD incidence or BW. decreased serum Ca and P concentrations and tartrate-resistant acid phosphatase activity. enhanced the total antioxidant capacity, superoxide dismutase, and glutathione peroxidase activities in the liver and kidney. Upregulated the expression of type X collagen, matrix metalloproteinase (MMP)-13, and Runx2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess the influence of thiram on the LH surge in intact rats, additional females were dosed at 1300 h on the day of proestrus and blood collected over that same day." | ( The dithiocarbamate fungicide thiram disrupts the hormonal control of ovulation in the female rat. Cooper, RL; Goldman, JM; Stoker, TE, ) | 0.71 |
| "Both disulfiram (tetraethylthiuram disulfide), an alcohol aversive drug, and thiram (tetramethyl-thiuram disulfide), a widely used pesticide, significantly increased the dopamine pool in the adrenal glands of dosed rats." | ( Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-beta-hydroxylase activity. Caroldi, S; De Paris, P, 1995) | 0.76 |
| " The sensitizing capacity of known allergens was quantified by dose-response modeling." | ( A quantitative method for assessing the sensitizing potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of the uncertainty margins. de Jong, WH; Slob, W; van Loveren, H; van Och, FM; Vandebriel, RJ, 2000) | 0.31 |
| " For the determination of potency based on lowest effective dose levels, dose-response studies are required." | ( Comparison of dose-responses of contact allergens using the guinea pig maximization test and the local lymph node assay. De Jong, WH; Prinsen, MK; Slob, W; van Loveren, H; van Och, FM; Vandebriel, RJ, 2001) | 0.31 |
| " SDS treatment with dosages of 10% and higher resulted in a SI above 3, while a dosage of 1% SDS showed no activity." | ( Determination of the sensitising activity of the rubber contact sensitisers TMTD, ZDMC, MBT and DEA in a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on local lymph node responses. De Jong, WH; Spiekstra, SW; Tentij, M; Van Loveren, H; Vandebriel, RJ, 2002) | 0.31 |
| " In 21-d-old broilers that had been fed a thiram-enriched diet (100 mg/kg of thiram for 2 d at 8 d old) to induce TD, intramuscular injection of the chVEGF proteins (at a dosage of 10 or 30 μg/kg) significantly reduced the severity of TD but had no effect on TD incidence or BW; decreased serum Ca and P concentrations and tartrate-resistant acid phosphatase activity and elevated serum alkaline phosphatase activity; enhanced the total antioxidant capacity, superoxide dismutase, and glutathione peroxidase activities in the liver and kidney; upregulated the expression of type X collagen, matrix metalloproteinase (MMP)-13, and Runx2; and downregulated the Bcl-2 expression in the growth plates." | ( Expression and identification of recombinant chicken vascular endothelial growth factor in Pichia pastoris and its role in the pathogenesis of tibial dyschondroplasia. Deng, YF; Hou, JF; Zhang, JP; Zhou, ZL, 2013) | 0.65 |
| " Specifically, we exposed cell lines established from bighead carp and silver carp larvae to thiram (7 concentrations) then completed metabolite profiling to assess the dose-response of the bighead carp and silver carp metabolome to thiram." | ( Using silver and bighead carp cell lines for the identification of a unique metabolite fingerprint from thiram-specific chemical exposure. Amberg, JJ; Erickson, RA; Hubert, TD; Leis, EM; Nelson, JE; Putnam, JG, 2017) | 0.89 |
| " In fat tissues, the key genes Lep, Nmb and Nmbr were altered in high dosed offspring, and were differentially expressed between sexes." | ( Effects on metabolic parameters in young rats born with low birth weight after exposure to a mixture of pesticides. Axelstad, M; Christiansen, S; Hass, U; Mandrup, K; Ramhøj, L; Svingen, T; Vinggaard, AM, 2018) | 0.48 |
| " The experimental plots were carried out on a clay loam soil and applied with three treatments namely; manufacturer's recommended dosage (25." | ( Evaluation of the Persistence and Leaching Behaviour of Thiram Fungicide in Soil, Water and Oil Palm Leaves. Halimah, M; Ismail, BS; Maznah, Z, 2018) | 0.73 |
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| antiseptic drug | A substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body). |
| antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organic disulfide | Compounds of structure RSSR in which R and R' are organic groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 19.9526 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 59.6217 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 22.7506 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2785; AID2787 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 6.3197 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 6.3197 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.3709 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 3.7212 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342; AID624030 |
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 49.2780 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347398 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 0.1259 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 3.5481 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 1.5393 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.2177 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 29.9002 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 27.4998 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 1.1220 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| GLS protein | Homo sapiens (human) | Potency | 27.7170 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 29.9002 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.1163 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2505 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 5.5448 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| AR protein | Homo sapiens (human) | Potency | 5.7025 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 3.5481 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 0.7943 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 0.2355 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 4.1814 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 19.9741 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 0.4335 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 8.6084 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.0964 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 21.8372 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 0.2030 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.6236 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.2885 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 7.3120 | 0.3758 | 27.4851 | 61.6524 | AID588527; AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 23.1565 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID1346985; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 11.9684 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| G | Vesicular stomatitis virus | Potency | 3.4671 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 0.9772 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| polyprotein | Zika virus | Potency | 1.1220 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 6.3359 | 0.0010 | 24.5048 | 61.6448 | AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 22.6153 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.5704 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743222; AID743223; AID743241 |
| caspase-3 | Homo sapiens (human) | Potency | 0.7943 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| IDH1 | Homo sapiens (human) | Potency | 0.0058 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.1905 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 0.5956 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.0839 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 34.4583 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259395 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.5514 | 0.1434 | 27.6121 | 59.8106 | AID1159519 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 35.6292 | 0.1549 | 17.8702 | 43.6557 | AID1346877 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 0.2082 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 0.2483 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 4.2203 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 0.6310 | 0.0058 | 6.0263 | 32.6427 | AID492947 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.4435 | 31.6228 | AID902 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 2.5119 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 0.8539 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 6.8660 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 63.0957 | 0.8913 | 16.5762 | 39.8107 | AID2794 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 44.9647 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 44.6684 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.1115 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 6.0448 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 0.1035 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| glyceraldehyde-3-phosphate dehydrogenase isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1.1220 | 11.1877 | 39.8107 | AID2795 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 1.0000 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 14.1254 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.3359 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 28.8366 | 0.0006 | 27.2152 | 1,122.0200 | AID720636; AID743202; AID743219 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 2.2387 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 2.2387 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 2.2387 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 0.6961 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 2.8184 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 7.6226 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 3.1623 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 11.9043 | 0.0056 | 12.3677 | 36.1254 | AID624032; AID624044 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 20.5324 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 1.1220 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 10.0000 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 1.0000 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 0.1084 | 0.0158 | 12.3113 | 615.5000 | AID1461; AID1489; AID2567 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 0.2336 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Interferon beta | Homo sapiens (human) | Potency | 3.4671 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 3.4671 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 49.8552 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 0.2336 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 5.0119 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 5.3080 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 0.7079 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.9811 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 3.4671 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 25.9949 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 24.0887 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 3.4671 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 29.1575 | 0.0601 | 10.7453 | 37.9330 | AID485367; AID492961 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Janus kinase 2 (a protein tyrosine kinase) | Homo sapiens (human) | IC50 (µMol) | 0.2230 | 0.2230 | 4.2372 | 7.5320 | AID1699 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 89.3200 | 3.9100 | 83.9944 | 180.9200 | AID1376 |
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | IC50 (µMol) | 44.6684 | 0.0002 | 0.5982 | 7.0000 | AID441698 |
| Gamma-butyrobetaine dioxygenase | Homo sapiens (human) | IC50 (µMol) | 23.5400 | 0.6900 | 3.1645 | 7.9000 | AID1166880; AID1166881; AID1166882; AID1166883; AID1166884 |
| Retinal dehydrogenase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0200 | 0.0200 | 1.0476 | 6.7900 | AID1762210 |
| Aldehyde dehydrogenase, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 0.3200 | 0.0400 | 3.4079 | 9.0000 | AID1762211 |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | IC50 (µMol) | 2.2900 | 0.0100 | 2.0097 | 9.8000 | AID1703767 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.0500 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| Protein-lysine 6-oxidase | Homo sapiens (human) | IC50 (µMol) | 1.0400 | 0.0100 | 1.1970 | 5.0000 | AID1399349 |
| Lysyl oxidase homolog 3 | Homo sapiens (human) | IC50 (µMol) | 0.1100 | 0.0930 | 0.1708 | 0.3100 | AID1399351 |
| Lysyl oxidase homolog 4 | Homo sapiens (human) | IC50 (µMol) | 0.1800 | 0.0590 | 0.1195 | 0.1800 | AID1399352 |
| Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | IC50 (µMol) | 0.5500 | 0.0025 | 1.1480 | 9.2000 | AID1374899 |
| Monoglyceride lipase | Homo sapiens (human) | IC50 (µMol) | 0.9772 | 0.0009 | 1.1268 | 10.0000 | AID441697 |
| Histone-lysine N-methyltransferase EHMT1 | Homo sapiens (human) | IC50 (µMol) | 1.1000 | 0.0130 | 0.7995 | 4.9000 | AID1374900 |
| Lysyl oxidase homolog 2 | Homo sapiens (human) | IC50 (µMol) | 0.1700 | 0.0660 | 0.5649 | 4.2600 | AID1399350 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| E3 ubiquitin-protein ligase Mdm2 isoform a | Homo sapiens (human) | EC50 (µMol) | 0.2200 | 0.0800 | 478.5789 | 4,301.1099 | AID1394; AID1442; AID1444 |
| Gamma-butyrobetaine dioxygenase | Homo sapiens (human) | Kd | 47.0000 | 3.6000 | 5.2667 | 7.6000 | AID1166891; AID1166892 |
| Substance-K receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.4000 | 0.0005 | 0.4964 | 3.1300 | AID1444 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 7.7410 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 3.9570 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 3.4000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 3.4000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1166881 | Inhibition of human BBOX pre-incubated for 10 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1378628 | Antifungal activity against Peronophythora litchii after 8 hrs by conidial germination assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. |
| AID1399354 | Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1295325 | Antifungal activity against Candida albicans after 48 hrs by broth microdilution method | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1374897 | Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1374900 | Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1399349 | Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1166891 | Binding affinity to human BBOX by tryptophan fluorescence quenching binding assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1374895 | Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1374902 | Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1295352 | Antitrichomonas activity against Trichomonas vaginalis assessed as reduction in free thiol levels in parasite membrane at MIC after 24 hrs by fluorescence microscopy | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1295334 | Selectivity index, ratio of IC50 for Lactobacillus jensenii ATCC 25258 to MIC for trophozoite stage of Trichomonas vaginalis clinical isolate | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1399350 | Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1762210 | Inhibition of ALDH1A1 (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 40 | Development of new disulfiram analogues as ALDH1a1-selective inhibitors. |
| AID1295336 | Potency index, ratio of metronidazole MIC to compound MIC for metronidazole-resistant trophozoite stage of Trichomonas vaginalis ATCC 50143 | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID89654 | Inhibition of HIV-1 replication in human T-cell by using XTT assay; Inactive | 1996 | Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19 | Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. |
| AID1295328 | Antifungal activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution method | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1378625 | Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. |
| AID1166892 | Binding affinity to human BBOX in presence of Fe(II) by tryptophan fluorescence quenching binding assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1295350 | Antitrichomonas activity against metronidazole-susceptible Trichomonas vaginalis in sc dosed mouse assessed as spleen weight at 5 ug administered daily measured after 7 days (Rvb = 0.59 g) | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1399356 | Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID441696 | Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate at 10 uM by liquid scintillation counting | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. |
| AID441697 | Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. |
| AID1295324 | Spermicidal activity in human sperms assessed as motility measured within 30 secs by phase contrast microscopy | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1166884 | Inhibition of human BBOX pre-incubated for 25 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1295333 | Cytotoxicity against human HeLa cells after 5 hrs by lactate dehydrogenase release assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1295329 | Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1295335 | Selectivity index, ratio of IC50 for Lactobacillus jensenii ATCC 25258 to MIC for metronidazole resistant trophozoite stage of Trichomonas vaginalis ATCC 50143 | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1399352 | Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1081280 | Antifungal activity against Botryotinia fuckeliana by mycelium growth rate test | 2010 | Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5 | Synthesis, fungicidal activity, and structure-activity relationship of spiro-compounds containing macrolactam (macrolactone) and thiadiazoline rings. |
| AID1295349 | Antitrichomonas activity against metronidazole-susceptible Trichomonas vaginalis in sc dosed mouse assessed as pustule formation at 5 ug administered daily measured after 7 days (Rvb = 190 mm'2) | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1081278 | Antifungal activity against Rhizoctonia solani Kuhn by mycelium growth rate test | 2010 | Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5 | Synthesis, fungicidal activity, and structure-activity relationship of spiro-compounds containing macrolactam (macrolactone) and thiadiazoline rings. |
| AID1378626 | Cytotoxicity against human A549 cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. |
| AID1399355 | Inhibition of recombinant human LOXL3 expressed in CHO cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1166882 | Inhibition of human BBOX pre-incubated for 15 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1081276 | Antifungal activity against Phomopsis asparagi by mycelium growth rate test | 2010 | Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5 | Synthesis, fungicidal activity, and structure-activity relationship of spiro-compounds containing macrolactam (macrolactone) and thiadiazoline rings. |
| AID1374898 | Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1378629 | Antifungal activity against Fusarium verticillioides after 8 hrs by conidial germination assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. |
| AID1295327 | Antifungal activity against Sporothrix schenckii after 48 hrs by broth microdilution method | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1166885 | Induction of Zn(II) from human BBOX assessed as zinc release by fluorescence based assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1295332 | Toxicity in Lactobacillus jensenii ATCC 25258 after 72 hrs | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1295326 | Antifungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution method | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1081277 | Antifungal activity against Magnaporthe oryzae by mycelium growth rate test | 2010 | Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5 | Synthesis, fungicidal activity, and structure-activity relationship of spiro-compounds containing macrolactam (macrolactone) and thiadiazoline rings. |
| AID441698 | Inhibition of human recombinant FAAH-maltose binding protein | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. |
| AID1295331 | Antitrichomonas activity against metronidazole-resistant trophozoite stage of Trichomonas vaginalis ATCC 50143 assessed as cell viability under anaerobic condition after 48 hrs by trypan blue exclusion assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1762211 | Inhibition of ALDH2 (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 40 | Development of new disulfiram analogues as ALDH1a1-selective inhibitors. |
| AID1295348 | Antitrichomonas activity against metronidazole-susceptible Trichomonas vaginalis in sc dosed mouse assessed as pustule formation at 5 ug administered daily measured after 5 days (Rvb = 109 mm'2) | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID1081279 | Antifungal activity against Sclerotinia sclerotiorum by mycelium growth rate test | 2010 | Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5 | Synthesis, fungicidal activity, and structure-activity relationship of spiro-compounds containing macrolactam (macrolactone) and thiadiazoline rings. |
| AID1374899 | Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID89802 | Inhibition of HIV-1 replication in a proliferating human T-cell line assayed using an XTT assay. | 1996 | Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19 | Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. |
| AID1374901 | Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1166883 | Inhibition of human BBOX pre-incubated for 20 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1166887 | Binding affinity to human BBOX assessed as quenching of intrinsic tryptophan fluorescence at 50 to 200 uM in absence of Fe(II) | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1166880 | Inhibition of human BBOX pre-incubated for 1 min using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay | 2014 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21 | Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase. |
| AID1378627 | Cytotoxicity against human HeLa cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | Antifungal and Cytotoxic β-Resorcylic Acid Lactones from a Paecilomyces Species. |
| AID1703767 | Inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3) using FBP as substrate by malachite green dye based assay | 2020 | European journal of medicinal chemistry, Oct-01, Volume: 203 | Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes. |
| AID1399351 | Inhibition of recombinant human LOXL3 expressed in CHO cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID1374896 | Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit | 2018 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). |
| AID1295330 | Antitrichomonas activity against trophozoite stage of Trichomonas vaginalis clinical isolate assessed as cell viability under anaerobic condition after 48 hrs by trypan blue exclusion assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology. |
| AID441792 | Selectivity ratio for human MGL activity to human recombinant FAAH | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. |
| AID1399353 | Inhibition of recombinant human LOX expressed in HEK293 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control | 2018 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18 | Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 252 (36.52) | 18.7374 |
| 1990's | 68 (9.86) | 18.2507 |
| 2000's | 93 (13.48) | 29.6817 |
| 2010's | 154 (22.32) | 24.3611 |
| 2020's | 123 (17.83) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (1.19%) | 5.53% |
| Reviews | 14 (1.85%) | 6.00% |
| Case Studies | 47 (6.23%) | 4.05% |
| Observational | 2 (0.26%) | 0.25% |
| Other | 683 (90.46%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||